AstraZeneca's Brilinta fails in peripheral artery disease trial

October 4, 2016 6:21 AM

3 0

AstraZeneca's Brilinta fails in peripheral artery disease trial

LONDON AstraZeneca said on Tuesday its heart drug Brilinta failed to show any benefit over an existing medicine in treating peripheral artery disease (PAD) in a large-scale clinical trial.

The company said it was disappointed that the drug, which is used to treat heart attack patients, had not been successful for PAD sufferers.

Read more

To category page

Loading...